Scientific name: 4-Bromo-2,5-dimethoxyphenethylamine (IUPAC: 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine)

Common names: 2C-B, Nexus, Spectrum

Chemical class: Substituted phenethylamine

Molecular formula: C₁₀H₁₄BrNO₂ (molecular weight: 243.13 g/mol)

Substance type: Synthetic compound with no known natural source

2C-B is a member of the 2C-X family, a group of phenethylamines characterized by a two-carbon ethylamine side chain attached to a substituted benzene ring. The "2C" in its name refers to this two-carbon backbone; the "B" denotes it as the bromine-substituted variant in Shulgin's naming system.

In its pure form, 2C-B appears as a white to off-white crystalline powder, soluble in ethanol and acidic solutions but poorly soluble in water. It is commonly encountered as pressed tablets, capsules, or loose powder.

Within the broader taxonomy of psychoactive substances, 2C-B sits among the classical psychedelics, sharing the 5-HT2A serotonin receptor agonism that defines this class. It is structurally related to mescaline (both are phenethylamines) but differs significantly in substitution pattern, potency, and experiential character.

2C-B is built on a simple architecture: a benzene ring carrying three substituents (a bromine atom at the 4-position and methoxy groups at positions 2 and 5) with a two-carbon ethylamine chain extending from the ring. The bromine atom is the defining feature. It is what gives 2C-B its particular pharmacological character, distinguishing it from the parent compound 2,5-dimethoxyphenethylamine, which is far less potent.

The molecule shares a structural kinship with serotonin. Both contain the phenethylamine backbone, the minimal scaffold that allows a compound to interact with serotonin receptors. Where serotonin has an indole ring (a fused two-ring system), 2C-B has a single benzene ring decorated with its bromine and methoxy groups. This similarity is the reason 2C-B can bind to the same receptors that serotonin normally occupies.

Primary mechanism of action

2C-B operates as an agonist at the 5-HT2A serotonin receptor, meaning it activates this receptor in a manner that mimics (and amplifies) certain effects of serotonin. The 5-HT2A receptor is the primary target for all classical psychedelics, and its activation in the prefrontal and visual cortex regions is what produces the characteristic perceptual shifts: geometric patterns, color intensification, and the sense that surfaces are breathing or flowing.

2C-B also activates the 5-HT2C receptor, which contributes to mood modulation. There is weaker interaction with 5-HT7 receptors, which may play a role in how time perception shifts during the experience. Importantly, 2C-B shows minimal binding to dopamine or adrenergic receptors, making its pharmacological profile relatively narrow compared to LSD, which engages a much broader range of targets.

What remains unknown

Direct binding affinity data for 2C-B is limited. Most published values derive from Alexander Shulgin's original 1994 characterization, which used non-standardized assays. Modern radioligand studies have not been published for 2C-B specifically. The compound's metabolism in humans is also largely uncharacterized: it is presumed to involve hepatic enzymes (likely CYP2D6 and monoamine oxidase), but no direct studies exist. Whether 2C-B produces active metabolites remains unknown.

Cross-tolerance with other 5-HT2A agonists (LSD, psilocybin) is well-reported by users, consistent with the shared receptor mechanism.

2C-B is entirely synthetic. There is no plant to harvest, no fungus to cultivate, no traditional preparation to learn. Every encounter with this compound begins with laboratory chemistry.

The most common form is oral ingestion, either as pressed tablets, capsules, or powder dissolved in liquid. This is the route most people use, and it produces the most predictable experience arc: onset typically begins 20 to 60 minutes after ingestion, with effects building gradually toward a peak at roughly two to three hours and resolving over four to six hours total. The gradual onset allows time for psychological adjustment as the perceptual shifts arrive.

Intranasal administration (insufflation of powder) produces a markedly different encounter. Onset is rapid, often within 5 to 15 minutes, and the experience tends to be shorter (two to four hours) but more intense per comparable amount. The speed of onset leaves little time for mental preparation, and the physical discomfort of nasal irritation and post-nasal drip can color the early part of the experience negatively. This route carries higher anxiety risk during the compressed come-up period.

Sublingual use (holding the substance under the tongue) falls between oral and intranasal: faster onset than swallowing, less physical discomfort than insufflation, with a total duration of roughly three to five hours.

Vaporization and injection are extremely rare and carry high unpredictability. These routes are poorly documented and not part of standard use contexts.

There are currently no clinical or therapeutic settings where 2C-B is administered. No approved trials exist, and no regulatory pathway for clinical use is open as of 2026. All encounters with this compound occur outside medical infrastructure, whether in private settings, social gatherings, or festival environments.

2C-B has no ancient roots, no ethnobotanical lineage, no ceremonial tradition to honor. Its entire history fits within a single human lifetime.

In 1974, Alexander Shulgin, a pharmacologist and chemist working from his private laboratory in Berkeley, California, synthesized 2C-B as part of a methodical investigation into how halogen atoms (bromine, iodine, chlorine) affect the pharmacology of phenethylamine compounds. He was not seeking a recreational drug. He was mapping a chemical landscape, testing each substitution to understand what it would do to receptor binding and subjective experience. The bromine atom at the 4-position turned out to produce a compound with distinctive properties: potent enough to be active at moderate amounts, short enough in duration to be practical for self-experimentation, and perceptually vivid.

Shulgin tested 2C-B on himself and a small circle of associates through the late 1970s, documenting his observations in the careful, qualitative style that would become his signature. For nearly two decades, the compound existed as a scientific curiosity known to a handful of chemists and pharmacologists.

That changed in 1995, when Shulgin and his wife Ann published PiHKAL: A Chemical Love Story, a book that detailed the synthesis, pharmacology, and personal experience notes for over 200 psychoactive compounds, including 2C-B. The publication coincided with the rapid expansion of the internet. Synthesis routes that had previously circulated through print and word-of-mouth became instantly accessible to chemists worldwide.

Clandestine production began in earnest, particularly in the Netherlands, Belgium, and Germany. By the late 1990s, 2C-B had entered the European electronic music and psytrance scenes under the street name "Nexus." It spread to North America in the early 2000s, though it never achieved the prevalence of LSD, MDMA, or psilocybin.

The scheduling wave began around 2001. Country after country classified 2C-B as a controlled substance, restricting both its sale and its potential for clinical research. By 2010, the compound's market presence had plateaued. The introduction of cheaper, more dangerous NBOMe compounds (sometimes fraudulently sold as 2C-B) eroded user confidence. Stricter precursor controls in China and India, where most illicit synthesis occurred, further reduced supply.

Today, 2C-B occupies a niche position: still available through specialized underground networks, but rare compared to its peak years. No pharmaceutical company has pursued it for therapeutic development. No clinical trial has been registered. It remains, as it began, a product of one chemist's curiosity, carried forward by a small community operating outside the law.

2C-B is one of the least-studied psychedelics in common use. Unlike psilocybin and LSD, which have decades of clinical research behind them, 2C-B has zero published human safety studies. This gap is not a reassurance of safety; it is an absence of knowledge.

Psychological risks

The most commonly reported adverse effect is acute anxiety during onset, occurring in roughly 10 to 15 percent of experiences. The rapid come-up, particularly via intranasal administration, can produce a sense of dread, racing heart, and catastrophic thinking that typically resolves within 30 to 60 minutes. Challenging emotional experiences occur in approximately 5 to 10 percent of sessions.

People with active psychotic disorders face serious risk. All 5-HT2A agonists can precipitate or worsen psychotic symptoms, and this contraindication is well-established across the psychedelic class. The same caution extends to those with a family history of psychosis. Severe anxiety disorders, PTSD, and active suicidality are also significant risk factors.

Physical considerations

2C-B is presumed to produce sympathomimetic effects (increased heart rate, elevated blood pressure) based on its phenethylamine chemistry, though these have not been directly measured in users. People with uncontrolled hypertension, cardiac arrhythmias, or cardiovascular history should consider this an important caution. Nausea, jaw tension, muscle tightness, and dry mouth are common.

Drug interactions

The most significant interaction is with MAOIs (monoamine oxidase inhibitors), carrying risk of hypertensive crisis. This is a genuine contraindication. SSRIs present a less clear picture: serotonin syndrome appears extremely rare with classical psychedelics, and many users on SSRIs report reduced effects rather than adverse reactions. Stimulants add cardiovascular stress. Tramadol and other serotonergic medications elevate serotonin syndrome risk.

Purity and identity

Because 2C-B exists outside regulated supply chains, every encounter carries uncertainty about what the substance actually is. NBOMe compounds (particularly 25B-NBOMe) have been sold fraudulently as 2C-B, carrying a dramatically different risk profile including severe vasoconstriction and documented fatalities. Reagent testing (Marquis combined with Mandelin) can help distinguish them, but no single test is fully confirmatory.

Set, setting, and support

Context shapes outcomes. Unfamiliar environments, poor psychological preparation, and the absence of trusted companions all increase the likelihood of a difficult experience. The presence of someone experienced and sober can make a meaningful difference in how challenging moments unfold.

The experience ends, but the processing does not. Integration is what happens in the hours, days, and weeks after a psychedelic encounter, the slow work of making sense of what was felt, seen, and understood.

2C-B presents a particular integration challenge. Its shorter duration means there is less time during the experience itself for insights to surface and settle. Some people find that the brevity leaves them with vivid impressions but fewer of the deep realizations that longer psychedelics tend to produce. Others appreciate the compression, finding that what emerged was clear enough to carry forward without weeks of unpacking.

Either way, the invitation is the same: pay attention to what arose, and give it room.

Practices that support integration

Journaling within the first 24 to 48 hours helps capture what is still vivid. Simple prompts can be useful: What surprised me? What felt uncomfortable, and why? What do I want to carry into daily life?

Rest is often underestimated. The nervous system has been through an unusual state, and sleep, quiet, and basic self-care support the body's return to equilibrium.

Conversation with a trusted person, whether a friend, a therapist, or a peer integration group, can help clarify what was experienced. Speaking an insight aloud sometimes reveals whether it holds weight or dissolves under examination.

Creative expression (drawing, writing, music, movement) can access parts of the experience that verbal processing does not reach.

Time and patience may be the most important elements. Integration is not a checklist. Some experiences take days to settle; others keep unfolding for weeks.

When integration is difficult

If the experience included anxiety, overwhelm, or unsettling content, the aftermath can feel heavier. This does not mean something went wrong. But if distress persists, particularly if it interferes with daily functioning or sleep, seeking support from a therapist familiar with psychedelic experiences is a reasonable step.

No clinical integration protocols exist for 2C-B, since no clinical trials have been conducted. The frameworks developed for psilocybin and MDMA-assisted therapy represent what a formalized version might look like.

2C-B carries no ecological footprint in the traditional sense. It is not harvested from endangered cacti or overpicked from forest floors. There is no indigenous community whose sacred relationship with this compound has been disrupted by Western demand. It is a molecule that exists because one chemist decided to put a bromine atom on a benzene ring.

But the absence of ecological harm does not mean the absence of ethical questions.

Access and equity

2C-B is illegal in virtually every jurisdiction where it is used. This criminalization does not distribute its consequences evenly. Enforcement of drug laws disproportionately affects communities of color and economically disadvantaged populations, a pattern that is well-established across the broader drug policy landscape. The people most likely to face legal consequences are not the same people most likely to use the compound.

Access itself is stratified. 2C-B is primarily available through specialized underground networks, concentrated in urban centers, and known to educated, internet-connected communities. It is not equally accessible, and the legal risks of obtaining it are not equally borne.

The commercialization question

Unlike psilocybin and MDMA, which are being developed into premium clinical therapies, 2C-B has attracted no pharmaceutical interest. No company holds patents on its therapeutic use. This means no corporate entity is working to make it medically available, but it also means no corporate entity is positioning itself to charge thousands of dollars per treatment session. Whether this absence represents a failure of development or a protection from commodification depends on perspective.

Legality is not morality

2C-B is classified alongside heroin and cocaine in many countries. Its scheduling reflects political and historical dynamics as much as pharmacological assessment. The legal status should be understood as a framework of rules that carries real consequences, not a definitive judgment on the compound's nature or value.